Melanotan I and Melanotan II are routinely grouped as a single "tanning peptide," but the published record treats them as two distinct compounds that differ in chemistry, receptor activity, regulatory standing, and risk. The honest bottom line up front is that one exists as a narrowly indicated, physician-supervised prescription medicine, while the other has never passed the safety and efficacy review that approval requires and reaches users only through unregulated channels.
| Criteria | Melanotan I (afamelanotide) | Melanotan II |
|---|---|---|
| Structure | Linear 13-amino-acid analog of alpha-MSH | Smaller cyclic peptide |
| Receptor activity | Relatively MC1R-selective | Broad: MC1R, MC3R, MC4R |
| Approval status | Approved as Scenesse (prescription) | No marketing authorization anywhere |
| Primary documented use | Photoprotection in erythropoietic protoporphyria | Informal cosmetic tanning |
Melanotan I, in its afamelanotide form, is an approved prescription medicine (Scenesse) for erythropoietic protoporphyria, while Melanotan II holds no marketing authorization in any major jurisdiction and circulates only through the unregulated research-chemical and cosmetic-tanning market.
The clearest dividing line between the two compounds is architectural. Melanotan I stays close to the natural alpha-melanocyte-stimulating hormone sequence, while Melanotan II trades that sequence fidelity for a compact, ring-closed shape, and that single structural difference is the mechanistic reason their receptor behavior diverges.
Melanotan I is a linear 13-amino-acid analog of alpha-MSH that remains comparatively confined to the pigmentation receptor, while Melanotan II is a smaller cyclic peptide whose ring closure underlies its broader, less predictable receptor activity.
Receptor selectivity is the pharmacological heart of the comparison. Skin pigmentation runs mainly through the MC1R receptor, and where Melanotan I concentrates much of its activity there, Melanotan II is a less discriminating agonist that also engages MC3R and MC4R. That difference in reach, not a difference in potency alone, is what separates a narrow, anticipated set of effects from a wide and harder-to-forecast one.
| Receptor | Melanotan I | Melanotan II |
|---|---|---|
| MC1R (pigmentation) | Primary target | Activated |
| MC3R | Minimal | Activated |
| MC4R (arousal, appetite) | Minimal | Activated |
| Effect breadth | Narrow, pigmentation-focused | Broad, multi-system |
Melanotan I preferentially activates MC1R for pigmentation, whereas Melanotan II also activates MC3R and MC4R, and MC4R activation in the central nervous system accounts for its reported effects on libido and appetite in addition to tanning.
On regulatory footing the two compounds could hardly stand further apart, and the gap is not a technicality. An approved product carries verified identity, purity, and dosing guidance, while an unapproved one reaches its users through channels that offer none of those assurances, which is the underlying reason the two invite different risk assessments before their pharmacology is even considered.
| Criteria | Melanotan I (afamelanotide) | Melanotan II |
|---|---|---|
| Marketing approval | Approved; sold as Scenesse | None in any major jurisdiction |
| Indication | Phototoxic reactions in EPP adults | No licensed indication |
| Manufacturing | Pharmaceutical standards | Not held to pharmaceutical standards |
| Oversight | Specialist medical supervision | None |
Afamelanotide has completed formal safety and efficacy review and is manufactured to pharmaceutical standards under specialist supervision, while Melanotan II has never completed the regulatory review that would establish its safety, efficacy, or dosing and is not a licensed medicine anywhere.
What each compound is used for tracks closely with its receptor profile, and the distinction between a reviewed medical endpoint and an unvalidated cosmetic one is the point most often blurred. One compound pursues a narrow, supervised clinical goal; the other is used off any approved label for a mix of cosmetic and lifestyle effects whose reported benefits sit outside any formal evaluation.
The approved use of Melanotan I is medical photoprotection in erythropoietic protoporphyria, while Melanotan II's cosmetic tanning and reported libido and appetite effects are unvalidated consequences of broad receptor activation with no regulated evidence base behind them.
Safety is where the practical stakes of the comparison concentrate. Melanotan II's broad melanocortin activity, its unapproved status, and its supply through unregulated channels compound one another, since a user of an unverified vial faces contamination and overdosing risk stacked on top of the compound's inherent pharmacology. The approved form of Melanotan I is not free of side effects, but it at least sits inside a monitored medical framework.
Melanotan II is commonly linked to nausea, blood-pressure changes, spontaneous erections, and darkening or changing moles, and its unregulated supply prevents any verification of identity, purity, or dose, while the long-term dermatological picture for both compounds, particularly any relationship to skin-cancer surveillance, remains incompletely characterized.
The routes by which people encounter these compounds are as different as their legal standing. The core problem is that the sourcing route directly governs how far the label can be trusted: a regulated prescription supply provides verified identity, purity, and dosing, while an unregulated supply offers none of those guarantees, so the same nominal peptide can vary widely in actual content from one vial to the next.
| Dimension | Melanotan I (afamelanotide) | Melanotan II |
|---|---|---|
| Channel | Specialist medical dispensing | Online research-chemical or tanning market |
| Prescription | Required | Sold without prescription |
| Manufacturer | Regulated pharmaceutical | Not held to pharmaceutical standards |
| Label trust | Verified identity and purity | Frequently labeled "not for human use" |
Melanotan I in its approved form is dispensed as a prescription medicine through regulated medical channels, while Melanotan II is typically marketed online as a research chemical or tanning aid, sold without prescription and often carrying a disclaimer that it is not for human use.
Administration underscores the same supervised-versus-informal divide seen everywhere else in the comparison. Where one compound is delivered by a defined medical protocol, the other has no established dosing standard at all, and that absence compounds the uncertainty already introduced by unregulated purity and broad receptor activity.
The approved form of Melanotan I is administered as a slow-release subcutaneous implant placed by a healthcare professional under a standardized regimen, whereas Melanotan II has no established dosing standard and is typically self-administered by subcutaneous injection of reconstituted powder at amounts copied from informal sources.
Educational use only. This article describes what the published scientific and clinical literature reports about Melanotan I and Melanotan II. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
